Literature DB >> 28948635

Validating effectiveness of subgroup identification for longitudinal data.

Nichole Andrews1, Hyunkeun Cho2.   

Abstract

In clinical trials and biomedical studies, treatments are compared to determine which one is effective against illness; however, individuals can react to the same treatment very differently. We propose a complete process for longitudinal data that identifies subgroups of the population that would benefit from a specific treatment. A random effects linear model is used to evaluate individual treatment effects longitudinally where the random effects identify a positive or negative reaction to the treatment over time. With the individual treatment effects and characteristics of the patients, various classification algorithms are applied to build prediction models for subgrouping. While many subgrouping approaches have been developed recently, most of them do not check its validity. In this paper, we further propose a simple validation approach which not only determines if the subgroups used are appropriate and beneficial but also compares methods to predict individual treatment effects. This entire procedure is readily implemented by existing packages in statistical software. The effectiveness of the proposed method is confirmed with simulation studies and analysis of data from the Women Entering Care study on depression.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  classification algorithm; effectiveness of subgrouping; personalized treatment; random effects linear model

Mesh:

Year:  2017        PMID: 28948635     DOI: 10.1002/sim.7500

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Authors:  Xuan Zhang; Jose de Leon; Benedicto Crespo-Facorro; Francisco J Diaz
Journal:  J Biopharm Stat       Date:  2020-06-08       Impact factor: 1.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.